Pharming Group N.V. announces today that the Extraordinary General Meeting of Shareholders (EGM) has adopted all proposals on the EGM agenda.

Pharming Group N.V. announces that Pharming’s management will participate in the following investor conference in the month of March:

Pharming Group N.V. confirms it will report its preliminary (unaudited) fourth quarter and full year 2024 financial results, for the period ended December 31, on Thursday, March 13, 2025.

Pharming Technologies B.V. increases its ownership in Abliva AB (publ) to 92.70 percent.

Pharming Group N.V. announces that Pharming’s management will participate in the following investor conference in the month of February:

On December 15, 2024, Pharming Technologies B.V. (“Pharming”), a wholly-owned subsidiary of Pharming Group N.V., announced a recommended cash offer to the shareholders of Abliva AB (publ) (“Abliva”) to tender all their shares in Abliva to Pharming at a price of SEK 0.45 in cash per share (the “Offer”). An offer document relating to the Offer was published on January 15, 2025.

Pharming Group N.V. announces it will hold an Extraordinary General Meeting of Shareholders (EGM) on March 4, 2025, at 14:00 CET.

Pharming Group N.V. announces today that the Board of Directors has nominated Fabrice Chouraqui to become Pharming’s new Executive Director and Chief Executive Officer, succeeding Sijmen de Vries.

Pharming Group N.V. today announced a recommended public cash offer to the shareholders of Abliva AB (“Abliva”) to acquire all issued and outstanding shares of Abliva.

Pharming Group N.V. announces positive topline results of data from its Phase III clinical trial (NCT05438407) evaluating the investigational drug leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, in children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS).